These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
301 related articles for article (PubMed ID: 19704055)
1. Maintenance therapy for ovarian cancer: of Helsinki and Hippocrates. McGuire WP J Clin Oncol; 2009 Oct; 27(28):4633-4. PubMed ID: 19704055 [No Abstract] [Full Text] [Related]
2. Phase III trial of observation versus six courses of paclitaxel in patients with advanced epithelial ovarian cancer in complete response after six courses of paclitaxel/platinum-based chemotherapy: final results of the After-6 protocol 1. Pecorelli S; Favalli G; Gadducci A; Katsaros D; Panici PB; Carpi A; Scambia G; Ballardini M; Nanni O; Conte P; J Clin Oncol; 2009 Oct; 27(28):4642-8. PubMed ID: 19704064 [TBL] [Abstract][Full Text] [Related]
3. [Choice of first-line chemotherapy for advanced ovarian cancer]. Tiuliandin SA Vopr Onkol; 1999; 45(4):350-4. PubMed ID: 10532090 [No Abstract] [Full Text] [Related]
4. [Paclitaxel (Taxol)--drug of choice in ovarian cancer]. Fishman A Harefuah; 1996 Apr; 130(8):557-60. PubMed ID: 8765885 [No Abstract] [Full Text] [Related]
5. Chemotherapy for ovarian cancer: an evidence-based approach. Geisler JP; Manahan KJ; Wiemann MC Minerva Ginecol; 2004 Dec; 56(6):539-45. PubMed ID: 15729206 [TBL] [Abstract][Full Text] [Related]
6. [The role of paclitaxel in the first line treatment of cancer of the ovary?]. Slimane K Bull Cancer; 2003 Mar; 90(3):202-3. PubMed ID: 12803089 [No Abstract] [Full Text] [Related]
7. [Pharmacotherapy in ovarian carcinoma]. Pfisterer J; Du Bois A MMW Fortschr Med; 2005 Oct; 147(43):34-6. PubMed ID: 16302419 [TBL] [Abstract][Full Text] [Related]
8. [Advanced cancer of the ovary. The paclitaxel-cisplatin combination as the first-line standard of treatment]. Pecorelli S Recenti Prog Med; 1999 Jun; 90(6):338-41. PubMed ID: 10399475 [No Abstract] [Full Text] [Related]
9. Recent advances in the treatment of gynecologic malignancies: an overview of the GOG phase III trials. Kim RY Gan To Kagaku Ryoho; 2002 Feb; 29 Suppl 1():125-40. PubMed ID: 11890098 [No Abstract] [Full Text] [Related]
10. Intraperitoneal cisplatin therapy in ovarian cancer: comparison with standard intravenous carboplatin and paclitaxel. Ozols RF; Bookman MA; du Bois A; Pfisterer J; Reuss A; Young RC Gynecol Oncol; 2006 Oct; 103(1):1-6. PubMed ID: 16904166 [No Abstract] [Full Text] [Related]
11. Is it time for some new approaches for treating advanced ovarian cancer? McGuire WP J Natl Cancer Inst; 2006 Aug; 98(15):1024-6. PubMed ID: 16882933 [No Abstract] [Full Text] [Related]
12. [Taxol in the treatment of ovarian neoplasm]. Wang Y; Huang R; Huang H Zhonghua Fu Chan Ke Za Zhi; 1999 Jul; 34(7):439-41. PubMed ID: 11360659 [No Abstract] [Full Text] [Related]
14. [Advances in the treatment of ovarian carcinoma]. Pfisterer J; du Bois A; Hilpert F; Wagner U; Meier W Dtsch Med Wochenschr; 2004 Feb; 129(8):379-84. PubMed ID: 14961446 [No Abstract] [Full Text] [Related]
15. Intraperitoneal therapy for advanced ovarian cancer: will it become standard care? Bankhead C J Natl Cancer Inst; 2006 Apr; 98(8):510-2. PubMed ID: 16622116 [No Abstract] [Full Text] [Related]
16. Time to include high-risk early ovarian cancer in randomized phase III trials of advanced ovarian cancer. Vergote I; Amant F Gynecol Oncol; 2006 Sep; 102(3):415-7. PubMed ID: 16979430 [No Abstract] [Full Text] [Related]
17. Advanced ovarian cancer: a clinical update on first-line treatment, recurrent disease, and new agents. Ozols RF J Natl Compr Canc Netw; 2004 Sep; 2 Suppl 2():S60-73. PubMed ID: 19780247 [TBL] [Abstract][Full Text] [Related]